Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Seldon

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patientsAndrew Spencer, Michael Seldon, Sandra Deveridge, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2004
Fatigue during breast radiotherapy and its relationship to biological factorsChristopher Wratten, Janice Kilmurray, Sharon Nash, et al.
Neoplasia (New York, N.Y.)|September 25, 2008
Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variantLisa F Lincz, Lisa-Maree Mudge, Fiona E Scorgie, et al.
Pathology|July 1, 2014
Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venomLisa F Lincz, Fiona E Scorgie, Christopher I Johnston, et al.
British Journal of Clinical Pharmacology|March 5, 2011
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 genePatricia McGettigan, Lisa F Lincz, John Attia, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 18, 2008
Thrombin generation as a predictor of radiotherapy induced skin erythemaLisa F Lincz, Sanjiv A Gupta, Christopher R Wratten, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patientsAndrew Spencer, Michael Seldon, Sandra Deveridge, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2004
Fatigue during breast radiotherapy and its relationship to biological factorsChristopher Wratten, Janice Kilmurray, Sharon Nash, et al.
Neoplasia (New York, N.Y.)|September 25, 2008
Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variantLisa F Lincz, Lisa-Maree Mudge, Fiona E Scorgie, et al.
Pathology|July 1, 2014
Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venomLisa F Lincz, Fiona E Scorgie, Christopher I Johnston, et al.
British Journal of Clinical Pharmacology|March 5, 2011
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 genePatricia McGettigan, Lisa F Lincz, John Attia, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 18, 2008
Thrombin generation as a predictor of radiotherapy induced skin erythemaLisa F Lincz, Sanjiv A Gupta, Christopher R Wratten, et al.
Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Pageof 3